Skip to main content

View full-text article in PMC

. 2022 Aug 5;17(8):e0268712. doi: 10.1371/journal.pone.0268712

Table 4. The odds of severity affected by immune cells in patients with COVID-19 per 100.

Immune cells	Model 1^*		Model 2^**
Immune cells	OR (95% CI)	P	OR (95% CI)	P
CD3⁺	0.90 (0.75–1.10)	0.06	0.90 (0.74–1.10)	0.074
CD4⁺	0.82 (0.67–0.99)	0.047	0.82 (0.67–1.00)	0.055
CD8⁺	1.00 (0.99–1.01)	0.99	1.00 (0.99–1.01)	0.99
CD16⁺	0.67 (0.37–1.22)	0.08	0.67 (0.37–1.22)	0.09
CD20⁺	0.82 (0.55–1.22)	0.28	0.87 (0.55–1.15)	0.38
CD16⁺CD56⁺	0.55 (0.20–1.49)	0.24	0.55 (0.20–1.49)	0.26

*unadjusted.

**adjusted for age, sex and comorbidity.